Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04456504 · ClinicalTrials.gov registry record · Phase 4
HepB-CpG Series for Healthcare Workers Who Are Hepatitis B Vaccine Nonresponders
A Phase 4 study, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 4
- Development phase
- 49
- Enrollment target
NCT04456504: Completed Phase 4 study, sponsored by University of Wisconsin, Madison.
NCT04456504 is a Phase 4 study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 49 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04456504, a Phase 4 study, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 49 participants
- Enrollment target
Study Summary
This study is being done to determine if healthcare workers who have previously failed to respond to hepatitis B vaccine series will respond to a hepatitis B with CpG adjuvant (hepB-CpG) (Heplisav-B)
Primary Outcome
Response is defined as AntiHBs \>10 mIU/ml following two doses of hepB-CpG
Interventions
- BIOLOGICAL Recombinant hepatitis B vaccine with CpG adjuvant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2020-09-15 |
| Est. Completion | 2023-12-06 |
| Phase | Phase 4 |
What the finished NCT04456504 record still lists
NCT04456504 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 1 intervention - of which Recombinant hepatitis B vaccine with CpG adjuvant is the first listed.
NCT04456504 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04456504 about?
NCT04456504 is a clinical study titled "HepB-CpG Series for Healthcare Workers Who Are Hepatitis B Vaccine Nonresponders". This study is being done to determine if healthcare workers who have previously failed to respond to hepatitis B vaccine series will respond to a hepatitis B with CpG adjuvant (hepB-CpG) (Heplisav-B)
What is the current status of trial NCT04456504?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 49 participants. The study started on 2020-09-15. Estimated completion is 2023-12-06.
What interventions are being tested in trial NCT04456504?
The interventions under investigation include: Recombinant hepatitis B vaccine with CpG adjuvant (BIOLOGICAL).
Who is sponsoring clinical trial NCT04456504?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04456504's enrollment target sits among peer trials
49 1323rd of 2000 higher than 670 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI